期刊
CANCER RESEARCH
卷 68, 期 22, 页码 9107-9111出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-2556
关键词
-
类别
资金
- NCI NIH HHS [R01 CA085492-06A1, R01 CA102162-06A1, U54 CA126505-030001, U54 CA126505, R01 CA102162, R01 CA085492] Funding Source: Medline
Therapies targeting transforming growth factor beta (TGF beta) signaling using neutralizing antibodies and small molecular inhibitors are in multiple clinical trails. However, TGF beta is known to work as both a tumor suppressor and a tumor promoter, and current knowledge does not provide sufficient information on what factors mediate this switch in function and when this switch occurs. Recent advances in multiple disciplines suggest that immune cells from the tumor host may provide the answer. [Cancer Res 2008;68(22):9107-11]
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据